Funded Biotechnology Startups in St Louis
11 funded biotechnology startups in st louis — recent funding rounds, disclosed amounts, and headquarters. Updated weekly, free to browse.
Disclosed funding in St. Louis biotech is concentrated around a single standout: Wugen raised $35M on 2026-07-08, which dwarfs the next-largest disclosed round of $30M (PierianDx on 2021-11-02). Beyond those two, the remaining disclosed amounts step down to $11M (Mazen Animal Health, 2022-05-25) and then $7M–$2M, indicating a heavy right tail rather than a uniform distribution.
The list also shows temporal breadth from 2020-09-16 (BioSTL) to 2026-07-08 (Wugen), but with multiple entries clustering in 2025–2023: Varro ($7M, 2025-10-20) and GenAssist ($80K, 2025-10-17) sit near Panome Bio ($6M, 2024-11-21) and several 2023 rounds (Omniose $3M on 2023-09-27; plus undisclosed entries on 2023-06-06). All 11 rows list St Louis, Missouri, and stage labeling is dominated by “Series Unknown,” which appears 5 times (Varro, GenAssist, Panome Bio, BIOIO, Omniose) out of the 11 companies shown.
Most recent rounds
11 shownRelated listings
Frequently asked
What are the largest disclosed rounds, and how concentrated are they?
The largest disclosed amount is Wugen at $35M (2026-07-08), followed by PierianDx at $30M (2021-11-02). After these, the next disclosed levels are $11M (Mazen Animal Health, 2022-05-25) and then $7M–$2M, so two rounds account for the top end while the rest trail off materially.
Are there noticeable time clusters in the most recent entries?
Yes. Multiple disclosed or labeled rounds appear across 2023–2025: Omniose has $3M on 2023-09-27, while three 2023-06-06 entries are undisclosed (HIVE Medical; InterShunt) alongside other 2023 activity, and 2025 includes two distinct disclosed amounts (GenAssist $80K on 2025-10-17; Varro $7M on 2025-10-20).
How much of the funding data is disclosed versus undisclosed?
8 of 11 rows include disclosed amounts, while 3 of 11 are “undisclosed” (BIOIO on 2024-02-06; HIVE Medical on 2023-06-06; InterShunt on 2023-06-06). That means any “largest” comparisons apply only within the disclosed subset.
Which stage labels dominate this biotech list, and is there a pattern in how rounds are categorized?
“Series Unknown” is the most frequent stage label: 5 of the 11 companies list Series Unknown (Varro, GenAssist, Panome Bio, BIOIO, Omniose). By contrast, only one row shows Series C (Wugen, 2026-07-08) and one shows Series A (Mazen Animal Health, 2022-05-25).
Are there outliers worth attention within the disclosed amounts?
GenAssist at $80K (2025-10-17) is the smallest disclosed amount on the list, sitting far below the next-smallest disclosed figure of $2M (BioSTL, 2020-09-16). On the upper end, Wugen’s $35M is also an outlier relative to the rest of the disclosed amounts beyond PierianDx’s $30M.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.